Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AbbVie Inc (ABBV)’s First Quarter: The Full Story of Humira And The 7 Dwarfs

Page 1 of 2

In its first four months of existence, AbbVie Inc (NYSE:ABBV) rewarded investors with gains of almost 26%. Going into month five, those gains seem likely to increase. The spinoff of Abbott Laboratories (NYSE:ABT) announced solid first-quarter results before the market opened on Friday. Shares increased more than 1% in early trading. Here are the highlights from the quarter.

By the numbers
AbbVie Inc (NYSE:ABBV) reported adjusted earnings for the first quarter of $0.68 per share. That result beat the company’s prior guidance as well as the average analyst estimate of $0.66 per share. On a GAAP basis, first-quarter diluted earnings were $0.60 per share.

The company announced first-quarter revenue of nearly $4.33 billion, which beat the consensus analysts’ estimate of $4.29 billion. This level reflects a 3.7% increase compared with first-quarter results from 2012, when the brands now belonging to AbbVie were part of Abbott. When the impact of foreign exchange fluctuations is excluded, revenue grew at an even more impressive 16% rate.

Behind the numbers
My nickname for AbbVie Inc (NYSE:ABBV)’s product lineup is “Humira and the Seven Dwarfs.” That moniker was certainly applicable to the first quarter.

Humira powered the company’s revenue, with sales totaling over $2.2 billion. This reflects a 16% year-over-year increase excluding the impact of foreign exchange. Humira sales in the U.S. grew 23.7%, driven largely by the launch of the drug as a treatment of ulcerative colitis.

AbbVie Inc (NYSE:ABBV) counts seven other drugs with sales exceeding $100 million during the first quarter. Of these “seven dwarfs,” only AndroGel experienced increased sales — by only 3.4% year over year. The company did see nice growth from lower-selling Creon during the quarter, though. Sales increased by 32.4% to $90 million.

Now that the spinoff and the “spinner,” Abbott, have both reported first-quarter results, how did the two compare? AbbVie looks to be the winner.

Abbott had pretty good results. Both companies beat earnings estimates. However, Abbott missed analysts’ revenue estimates, while AbbVie Inc (NYSE:ABBV) topped revenue expectations. Round one to the spinoff.

Page 1 of 2
Loading Comments...